Skip to content

Study · In vitro (cells) · 1990

6 results

In vitro differentiation of human neuroblastoma cells caused by vasoactive intestinal peptide.

Pence JC, Shorter NA

Cancer research1 Aug 1990Cited by 53 (Europe PMC)

PMID2379178 (opens in a new tab)PepBankPUB-02379178
Publisher pageAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In human neuroblastoma cell lines LA-N-5 and IMR-32, VIP induced in vitro differentiation.

    In plain wordsIn cells, VIP made human neuroblastoma cell lines mature (differentiate).

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseNeuroblastoma cell differentiation
    Study

    humann: not reported in source

    human neuroblastoma cell lines LA-N-5 and IMR-32
    Outcome group
    Tumor growth · Cancer
    Studied dose
    different concentrationsAs given in this study (human).

    Source sentences

    Summary
    It is now shown that VIP also induces in vitro differentiation of these neuroblastoma lines.
    1 context sentence
    Summary · context
    LA-N-5 or IMR-32 cells were grown in the presence of different concentrations of VIP.
  2. 02LabIn vitro (cells)Activity measurement

    In LA-N-5 and IMR-32 neuroblastoma cells, VIP suppressed cell proliferation, measured by cell count, thymidine incorporation and proliferation index.

    In plain wordsIn cells, VIP slowed the growth of neuroblastoma cells.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseCell proliferation
    Study

    humann: not reported in source

    human neuroblastoma cell lines LA-N-5 and IMR-32
    Outcome group
    Tumor growth · Cancer
    Studied dose
    different concentrationsAs given in this study (human).

    Source sentences

    Summary
    Cell proliferation was suppressed, as measured by cell count, incorporation of [3H]thymidine, and measurement of the proliferation index.
    1 context sentence
    Summary · context
    LA-N-5 or IMR-32 cells were grown in the presence of different concentrations of VIP.
  3. 03LabIn vitro (cells)Activity measurement

    In LA-N-5 and IMR-32 cells, suppression of proliferation correlated with VIP concentration and was indistinguishable, on a molar basis, from that of retinoic acid.

    In plain wordsIn cells, VIP slowed neuroblastoma cell growth with the dose, and as strongly as retinoic acid.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeProliferation suppression, VIP versus retinoic acid
    Study

    humann: not reported in source

    human neuroblastoma cell lines LA-N-5 and IMR-32
    Comparator
    Retinoic acid
    Outcome group
    Tumor growth · Cancer
    Studied dose
    different concentrationsAs given in this study (human).

    Source sentences

    Summary
    The degree of suppression correlated with the concentration of VIP, and the effect was indistinguishable, on a molar basis, from that seen when cells were treated with retinoic acid.
    1 context sentence
    Summary · context
    LA-N-5 or IMR-32 cells were grown in the presence of different concentrations of VIP.
  4. 04LabIn vitro (cells)Activity measurement

    In LA-N-5 and IMR-32 cells, VIP caused morphological changes that were the same as those seen with retinoic acid.

    In plain wordsIn cells, VIP changed the shape of neuroblastoma cells in the same way as retinoic acid.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseMorphological changes
    Study

    humann: not reported in source

    human neuroblastoma cell lines LA-N-5 and IMR-32
    Comparator
    Retinoic acid
    Outcome group
    Tumor growth · Cancer
    Studied dose
    different concentrationsAs given in this study (human).

    Source sentences

    Summary
    Similarly, the morphological changes seen in the VIP-treated cells were the same as those seen in retinoic acid-treated ones.
    1 context sentence
    Summary · context
    LA-N-5 or IMR-32 cells were grown in the presence of different concentrations of VIP.
  5. 05LabIn vitro (cells)Activity measurement

    In LA-N-5 and IMR-32 cells, the effects of VIP were reversible, like those of retinoic acid.

    In plain wordsIn cells, the effects of VIP on neuroblastoma cells were reversible.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableReversibility of VIP effects
    Study

    humann: not reported in source

    human neuroblastoma cell lines LA-N-5 and IMR-32
    Outcome group
    Tumor growth · Cancer
    Studied dose
    different concentrationsAs given in this study (human).

    Source sentences

    Summary
    The effects of VIP on both cell lines, like those of retinoic acid, are reversible.
    1 context sentence
    Summary · context
    LA-N-5 or IMR-32 cells were grown in the presence of different concentrations of VIP.
  6. 06LabIn vitro (cells)Activity measurement

    In the human neuroepithelioma line CHP-100, sensitivity to VIP was much lower than in the neuroblastoma lines.

    In plain wordsIn cells, a related human tumour cell line was much less sensitive to VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableSensitivity of CHP-100 cells
    Study

    humann: not reported in source

    human neuroepithelioma cell line CHP-100
    Outcome group
    Tumor growth · Cancer
    Studied dose
    different concentrationsAs given in this study (human).

    Source sentences

    Summary
    The human neuroepithelioma line CHP-100, is much less sensitive to either agent.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.